Astrazeneca Pharma India LtdNSE: ASTRAZEN
Open the Astrazeneca Pharma India Ltd page
Follow Astrazeneca Pharma India LtdFree account. Get a note when Astrazeneca Pharma India Ltd files.
Q2 FY27 results analysis · November 05, 2026

Astrazeneca Pharma India Q2 FY27 Results Analysis: Revenue Surges 30%, NPPA Overhang Persists

+15.0%PAT year on year, Rs. 62.33 Cr
Cofacto ResearchPublished November 05, 20264 min readPositive read
Quick summary

Astrazeneca Pharma India Ltd's Q2 FY27 numbers came in strong, with revenue of Rs. 729.10 Cr (+30.41% YoY) and PAT growth of +14.96% YoY. Here's a quick read of what worked, what to watch, and what management said.

Quick Details
Results dateNovember 05, 2026
Revenue (Q2)Rs. 729.10 Cr (+30.41% YoY)
PAT (Q2)Rs. 62.33 Cr (+14.96% YoY)
EBITDA margin13.11% (-34 bps YoY)
EPS (Q2)Rs. 24.93 (+14.94% YoY)

Quarter Snapshot

Revenue grew 30.41% YoY to Rs.729.10 Cr, roughly 2x the Indian Pharma Market's ~14.7% growth, with normalized PAT up 25.29% and margins stabilizing after Q1's distortions. Cash conversion flipped sharply positive (H1 CFO of Rs.232.38 Cr vs an outflow last year) on a debt-free balance sheet with ~Rs.479 Cr net cash. The key overhang is the unprovided Rs.151.20 Cr NPPA demand, with the Delhi HC hearing on 11-Jan-2027, alongside a ~700 bps YoY goods-cost ratio increase from imported-cost and FX pressure.

Q2 FY27 Expectations vs Results

DriverExpected before resultsWhat happenedVerdict
Revenue"ahead" — growth "well ahead of the IPM" (+14.7% Q2 IPM)Revenue +30.41% YoY (Rs.729.10 Cr)Played out
Margins"likely compressing, but with normalization help"Pre-exceptional EBITDA margin 13.11% vs 13.45% YoY (−34 bps) but +594 bps QoQ; PBT-pre-exc margin 14.19% vs 13.97% YoYPartially
Employee costsnormalize after Q1 severance spikeRs.67.85 Cr: +12.24% YoY, −14.29% QoQPlayed out
FX on goods cost"lands directly on the biggest cost line"Goods-cost ratio 64.99% vs 58.04% YoY; purchases +44.33% YoYPlayed out
Inventory distortion eases"room to normalize toward purchase-flow"Q2 build Rs.(150.25) Cr vs Q1 drawdown +Rs.142.59 Cr; goods-cost 64.99% vs Q1 65.50% — stabilized, not restored to 58%Partially
NPPA provisioning call"a Q2/H1 disclosure question"No provision made; demand Rs.151.20 Cr; HC relief to 11-Jan-2027Played out
Betaloc-50 15% deposit"could show up in cash flows"No deposit or quantification in the filingNot observable
H2 trade-margin cap"direct H2 realized-price/channel-economics item"Not addressed in the filing — remains open for the callNot observable

Read our full results preview.

Management Guidance vs Delivery

What management saidWhereWhat happenedVerdict
"Track record of consistent double-digit growth over the last five years" (Q1 FY27 press release)Q1 FY27 press release, per prior analyst notesQ2 revenue +30.41% YoY, 13th data point of double-digit YoY growth visible across FY26 (+32.59%) and Q1 (+29.75%)Confirmed
"Continue to prioritise investments in its focus disease areas"FY26 Annual Report, per prior analyst notesH1 other expenses +12.35% YoY, below revenue growth; employee costs +17.70% H1 — investment growing but not out of controlConfirmed
Rare Disease launch pipeline spanning 2027–2029; "2–3 COEs by year-end"FY26 Annual Report / management commentary, per prior analyst notesNo Rare Disease revenue split disclosed this quarterToo Early
"Well-positioned to continue building momentum"Q1 FY27 press release, per prior analyst notesQ2 revenue +30.41%, pre-exceptional PBT +32.44%Confirmed

Key Investment Insights

Key Positives

  • Revenue grew 30.41% YoY to Rs.729.10 Cr, ~2x the Indian Pharma Market's ~14.7% Q2 growth
  • Pre-exceptional PBT grew 32.44% YoY, slightly ahead of revenue growth
  • Normalized PAT grew 25.29% YoY to Rs.72.87 Cr after adding back the Rs.15.61 Cr BBMP provision
  • Pre-exceptional EBITDA margin recovered to 13.11% from 7.17% in Q1, with PBT-pre-exceptional margin up 22 bps YoY at 14.19%
  • H1 operating cash flow of Rs.232.38 Cr (2.32x PAT) vs a Rs.65.73 Cr outflow in H1FY26; FCF of Rs.216.79 Cr
  • Zero borrowings with net cash of ~Rs.478.93 Cr; cash rose Rs.126.09 Cr in the half to Rs.573.81 Cr
  • Employee costs grew 12.24% YoY, slower than revenue, after Q1's severance spike normalized
  • Manufacturing-site disposal progressing; assets held for sale fell to Rs.3.61 Cr from Rs.7.74 Cr

Risk Factors

  • NPPA demand of Rs.151.20 Cr (incl. interest) for alleged overcharging remains unprovided — equal to ~1.36x normalized H1 PAT; Delhi HC interim relief runs only to the 11-Jan-2027 hearing
  • Goods-cost ratio at 64.99% is ~700 bps above the year-ago 58.04% on imported-goods cost pressure (purchases +44.33% YoY vs revenue +30.41%)
  • Effective tax rate stepped up to 29.56% from 25.54% YoY, a ~Rs.4 Cr drag on PAT
  • H1 normalized PAT is still down 2.68% YoY due to Q1's weak print
  • Post-quarter trade-margin cap on 137 anti-cancer drugs (effective 9-Nov-2026) is an unaddressed H2 pricing headwind

Ask about this

Ask Cofacto a question about this result. Answers cite filings and company data.

Companies on this page

Related

Share on X · LinkedIn · WhatsApp

Disclaimer: This results analysis is published for educational and informational purposes only. It is not investment advice, not a recommendation to buy, sell or hold any security.